sb 239063 has been researched along with Hypertrophy, Left Ventricular in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Boer, RA | 1 |
| Pokharel, S | 1 |
| Flesch, M | 1 |
| van Kampen, DA | 1 |
| Suurmeijer, AJ | 1 |
| Boomsma, F | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Pinto, YM | 1 |
1 other study available for sb 239063 and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atr | 2004 |